<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Therapy characteristics and response to induction therapy</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>≤ 65 years old</th>
    <th>ASCT &gt; 65 years old</th>
    <th>No ASCT ≥ 65 years old</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="4">Induction chemotherapy</td>
   </tr>
   <tr>
    <td> Bortezomib-based (
     <italic>n</italic>)
    </td>
    <td>71 (69%)</td>
    <td>22 (76%)</td>
    <td>15 (65%)</td>
   </tr>
   <tr>
    <td> IMiD-based (
     <italic>n</italic>)
    </td>
    <td>3 (3%)</td>
    <td>3 (10%)</td>
    <td>4 (17%)</td>
   </tr>
   <tr>
    <td> Bortezomib + IMiDs (
     <italic>n</italic>)
    </td>
    <td>27 (26%)</td>
    <td>4 (14%)</td>
    <td>3 (13%)</td>
   </tr>
   <tr>
    <td> Neither (
     <italic>n</italic>)
    </td>
    <td>2 (2%)</td>
    <td>0</td>
    <td>1 (5%)</td>
   </tr>
   <tr>
    <td colspan="4">Response to therapy</td>
   </tr>
   <tr>
    <td> CR (
     <italic>n</italic>)
    </td>
    <td>29 (28%)</td>
    <td>7 (24%)</td>
    <td>8 (35%)</td>
   </tr>
   <tr>
    <td> VGPR (
     <italic>n</italic>)
    </td>
    <td>46 (45%)</td>
    <td>13 (45%)</td>
    <td>7 (30%)</td>
   </tr>
   <tr>
    <td> PR (
     <italic>n</italic>)
    </td>
    <td>27 (26%)</td>
    <td>9 (31%)</td>
    <td>5 (22%)</td>
   </tr>
   <tr>
    <td> Refractory/stable (
     <italic>n</italic>)
    </td>
    <td>1 (1%)</td>
    <td>0</td>
    <td>3 (13%)</td>
   </tr>
   <tr>
    <td> &gt; 2 lines of treatment for better response (
     <italic>n</italic>)
    </td>
    <td>13 (12%)</td>
    <td>6 (21%)</td>
    <td>3 (13%)</td>
   </tr>
   <tr>
    <td> Time to transplant (median months)</td>
    <td>8 (3; 21)</td>
    <td>9 (4; 20)</td>
    <td>NA</td>
   </tr>
   <tr>
    <td colspan="4">Mobilization regimen</td>
   </tr>
   <tr>
    <td> HD-Cy + GCSF (
     <italic>n</italic>)
    </td>
    <td>78 (76%)</td>
    <td>25 (86%)</td>
    <td>NA</td>
   </tr>
   <tr>
    <td> G-CSF only (
     <italic>n</italic>)
    </td>
    <td>25 (24%)</td>
    <td>4 (14%)</td>
    <td>NA</td>
   </tr>
   <tr>
    <td> CD34+ collected (median × 10
     <sup>6</sup>/kg)
    </td>
    <td>6.5 (2.2; 35)</td>
    <td>5.0 (1.6; 19)</td>
    <td>NA</td>
   </tr>
   <tr>
    <td> Number of apheresis ≥ 3</td>
    <td>23 (22%)</td>
    <td>8 (27%)</td>
    <td>NA</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>IMiDs</italic>, immunomodulatory drugs; 
   <italic>HD-Cy</italic>, high-dose cyclophosphamide; 
   <italic>G-CSF</italic>, granulocyte colony-stimulating factor
  </p>
 </table-wrap-foot>
</table-wrap>
